HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossini, P. M. Articles by Stanzione, P. Search for Related Content PubMed PubMed Citation Articles by Rossini, P. M. Articles by Stanzione, P.

Parkinson's disease and somatosensory evoked potentials

Apomorphine-induced transient potentiation of frontal components

Ospedale s. Giovanni Calibita Fatebenefratelli (Drs. Rossini, Boccasena, Martino, Passarelli, and Pacifici), Isala Tiberina; the Clinica Neurologica (Drs. Traversa, Bernardi, and Stanzione), II Università di Roma "Tor Vergata"; and the Istituto di Ricovero e Cura a Carattere Scientifico "S. Lucia" (Drs. Traversa, Bernardi, and Stanzione), Rome, Italy.

We recorded somatosensory evoked potentials (SEPs) to median nerve stimulation from parietal and frontal districts in 32 patients with Parkinson's disease by evaluating latency/amplitude characteristics of the parietal P14-N20-P25 and of the frontal P20-N30-P40 wave complexes before and 10, 20, 30, and 60 minutes after subcutaneous administration of apomorphine chloride. The frontal complex N30-P40 was smaller than normal in 17 patients in baseline recordings. Following apomorphine, the parietal responses did not significantly vary in amplitude, but the frontal complex showed a remarkable amplitude potentiation in 22 of 32 patients (68.7%, p < 0.001), 19 of whom were also improving clinically. Amplitude potentiation was evident 10 minutes after apomorphine and faded away nearly in parallel with the end of its clinical efficacy. There were no SEP changes in three healthy controls after apomorphine.

Address correspondence and reprint requests to Dr. Paolo M. Rossini, Divisione di Neurologia, Ospedale F.B.F. Isola Tiberina, 39, 00186-Rome, Italy.

Received December 12, 1992. Accepted for publication in final form May 12, 1993.

This article has been cited by other articles:

				A. Sailer, G. F. Molnar, G. Paradiso, C. A. Gunraj, A. E. Lang, and R. Chen Short and long latency afferent inhibition in Parkinson's disease Brain, August 1, 2003; 126(8): 1883 - 1894. [Abstract] [Full Text] [PDF]

				T J Loher, J-M Burgunder, S Weber, R Sommerhalder, and J K Krauss Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson's disease J. Neurol. Neurosurg. Psychiatry, October 1, 2002; 73(4): 395 - 399. [Abstract] [Full Text] [PDF]

				M. Ulivelli, S. Rossi, P. Pasqualetti, P. M. Rossini, O. Ghiglieri, S. Passero, and N. Battistini Time course of frontal somatosensory evoked potentials: Relation to L-dopa plasma levels and motor performance in PD Neurology, October 22, 1999; 53(7): 1451 - 1451. [Abstract] [Full Text] [PDF]

				H. Boecker, A. Ceballos-Baumann, P. Bartenstein, A. Weindl, H. R. Siebner, T. Fassbender, F. Munz, M. Schwaiger, and B. Conrad Sensory processing in Parkinson's and Huntington's disease: Investigations with 3D H215O-PET Brain, September 1, 1999; 122(9): 1651 - 1665. [Abstract] [Full Text] [PDF]